drugset / Trial / NCT05140811
A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
Phase 1/2
Unknown
126 enrolled
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Institute of Hematology & Blood Diseases Hospital, China · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This trial is an open-lable , multi-center, Phase 1/Phase 2 study that will evaluate the safety, tolerability, Pharmacokinetics, Pharmacodynamics and and immunogenicity of IMM01 combined with Azacitidine in patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).
Timeline
- Start
- 2022-01-05
- Primary completion
- 2024-02-05
- Completion
- 2024-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 75 unknown | Subcutaneous |
| Subject | IMM01 | Protein / enzyme biologic | — | Intravenous |